Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A

Abstract

The invention involves viral vectors that can be used to tranduce a target cell, i.e. to introduce genetic material into the cell. The targets of interest are eukaryotic cells and particularly human cells. The transduction can be done in vivo or in vitro. More particularly the invention concerns viral vectors that have chimeric envelope proteins and contain the IgG-binding domain of protein A. These vectors when used in conjunction with antibodies targeting a particular cell are particularly useful for gene therapy.

Description

1. FIELD OF THE INVENTION[0001] The invention involves viral vectors that can be used to transduce a target cell, i.e., to introduce genetic material into the cell. The targets of interest are eukaryotic cells and particularly human cells. The transduction can be done in vivo or in vitro. More particularly the invention concerns viral vectors that have chimeric envelope proteins and contain the IgG-binding domain of protein A. These vectors when used in conjunction with antibodies targeting a particular cell are particularly useful for gene therapy.2. BACKGROUND OF THE INVENTION[0002] A variety of viral based vectors have been employed to transfer and to express a gene of interest into a eukaryotic target cell. Recombinant DNA techniques are used to replace one or more of the genes of the virus with the gene of interest operably linked to a promoter that is functional in the target cell. The construct, termed a viral vector, infects the target cell, using the physiological infective...

AI Technical Summary

Problems solved by technology

Secondly, there are well developed techniques to produce a stock of infectious vector particles that do not cause the production of viral particles in the transduced target cell.

One disadvantage of the use of retroviral vectors is that there is presently no practical general, method whereby a particular tissue or cell type of interest can be specifically transduced.

The technical difficulties of the ex vivo culture technique combined with the unavailability of growth factors of specific for some types of cells have limited the application of this approach.

A second difficulty presented by the use retroviral based vectors is that a recombination may occur between sequences of vector and an endogenous retrovirus.

Because of their ability to infect such a broad spectrum of cells, a major drawback to the use of amphotropic virus vectors is the fact that these vectors lack target-cell specificity.

However, this type of approach suffers from at least two limitations.

Second, virions constructed to directly bind to specific targets in human cells are intrinsically unsafe, as wild-type recombinants could produce potentially harmful effects patients treated with such vectors.

The method of Neda results in a variable number of binding sites for the exposed acceptor on the target cell, attached to each derivatized or bound envelope protein and, of course, is limited to the case wherein the target cell has a lactose receptor.

However, a major drawback to the use of Sindbis virus vectors is the fact that these vectors lack target-cell specificity.

Images